These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 2353405

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antihypertensive therapy in diabetic patients.
    Weidmann P, Boehlen LM, de Courten M, Ferrari P.
    J Hum Hypertens; 1992 Dec; 6 Suppl 2():S23-36. PubMed ID: 1289510
    [Abstract] [Full Text] [Related]

  • 6. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E, Muiesan ML.
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [The value of angiotensin-converting enzyme inhibitors in the treatment of hypertension].
    Klaus D.
    Z Kardiol; 1988 Jan; 77 Suppl 3():73-88. PubMed ID: 3062960
    [Abstract] [Full Text] [Related]

  • 9. Treatment of left ventricular hypertrophy in hypertensive patients.
    Tamargo J, Delpón E, Valenzuela C.
    Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
    [Abstract] [Full Text] [Related]

  • 10. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cardiovascular structural changes in hypertension: possible regression during long-term antihypertensive treatment.
    Novo S, Abrignani MG, Corda M, Strano A.
    Eur Heart J; 1991 Dec; 12 Suppl G():47-52. PubMed ID: 1839619
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 16. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH.
    Med Klin (Munich); 2003 Dec 15; 98(12):771-5. PubMed ID: 14685679
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Differential therapy of exercise hypertension].
    Klaus D.
    Herz; 1987 Apr 15; 12(2):146-55. PubMed ID: 3583208
    [Abstract] [Full Text] [Related]

  • 19. Hypertensive heart disease--significance of left ventricular hypertrophy.
    Schmieder RE.
    J Cardiovasc Pharmacol; 1992 Apr 15; 20 Suppl 6():S50-5. PubMed ID: 1283190
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T, Linjer E, Hedner T, Lanke J, De Faire U, Wester PO, Dahlöf B, Scherstén B.
    Blood Press; 2004 Apr 15; 13(3):137-41. PubMed ID: 15223721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.